A clinical trial comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i in subjects with type 2 diabetes mellitus
Phase of Trial: Phase III
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Insulin degludec/liraglutide (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DUAL IX
- Sponsors Novo Nordisk
- 26 Oct 2017 Status changed from recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 26 May 2016 Status changed from not yet recruiting to recruiting.